Common side effects include: Injection site reactions mild pain, redness, swelling, or bruising at the injection site, typically resolving within a few days Headache usually transient and manageable with standard analgesia Nausea or dizziness particularly in the initial treatment phase Skin reactions including itching, mild rash, or acneiform eruptions Temporary urine discolouration red or orange urine is harmless and expected Diarrhoea or flushing usually mild and self-limiting In patients with severe megaloblastic anaemia, low potassium levels (hypokalaemia) may occur during initial intensive treatment, but this is uncommon in routine maintenance therapy
Studies in animal models of inflammatory bowel disease (IBD) demonstrate BPC-157 can reduce inflammation, promote mucosal healing, and protect against intestinal damage
Proper storage: Peptides degrade if improperly stored
This one strategy, acknowledged by many experienced researchers and clinicians, prevents a huge amount of unnecessary suffering and premature discontinuation
Trapped blood volume redistribution rapidly occurred throughout rapid presentation of collaterals (Vukojevic et al., 2018
